SRC and gastric cancer: Compared with various signalling pathway inhibitors including LY294002 (PI3K/Akt activation inhibitor), U0126 (ERK1/2 activation inhibitor), SB203580 (p38 MAPK inhibitor), XAV939 (β‐catenin inhibitor) and SP600125 (JNK1/2 inhibitor), the findings indicated that Src mainly mediates IL‐8‐up‐regulated motility activity through modulating the activation of Cas, paxillin, EKR1/2 and JNK1/2 signalling pathways and the expression of invasive proteins MMP9, tPA and uPA in human gastric cancer cells.